Abstract 19810: Characterization of Lesions Created by a Heated, Saline Irrigated Needle-Tip Catheter in the Normal and Infarcted Canine Heart
Background: Inability to eliminate intramural arrhythmogenic substrates is one of the reasons for recurrent VT after catheter ablation in patients with sustained ventricular tachycardia (VT). The aim of the present study was to evaluate intramural lesion formation using a SERF (saline enhanced radiofrequency) needle-tip catheter, compared to a conventional ablation catheter in normal and dogs with healed myocardial infarction (MI).
Methods and Results: Twenty-two adult mongrel dogs (30-40 kg, 15 normal, 7 MI group) were studied. Lesions were created using the SERF catheter or a standard contact force catheter (SC) in normal and MI dogs. Comparing SERF to SC ablation, SERF (40W/50°C) produced larger lesion volumes than the SC - even with contact force (CF) of >20g - in both normal and infarcted left ventricular (LV) myocardium (983.1±905.8 vs. 461.9±178.3 mm3; p=0.005, normal dogs, 1052.3±543.0 vs. 340.3±160.5 mm3; p<0.001, MI dogs) (Figure 1A and 2A). SERF (40W/50°C) lesions were more often transmural than SC lesions with CF of >20g in both groups (59.1% vs. 7.7%; p=0.001, normal dogs, 60.0% vs. 12.5%; p=0.029, MI dogs). Using SERF, the mean depth of ablated lesions reached 90% of the LV wall in both normal and MI dogs (Figure 1B and 2B). Comparing SERF lesions (40W/50°C), in normal to lesions in myocardium with infarct scar, there were no significant difference in lesion volume (p=0.338).
Conclusions: The SERF catheter created more often transmural and larger ablative lesions in both normal and infarcted canine myocardium. SERF ablation size does not seem to be affected by the presence of scar tissue.
Author Disclosures: A. Suzuki: None. H. Lehmann: None. S. Wang: None. K.D. Parker: None. M. Rettmann: None. K.B. Viker: None. S.B. Johnson: None. D.L. Packer: Research Grant; Significant; American Heart Association Foundation Award, Biosense Webster, Boston Scientific/EPT, CardioInsight, CardioFocus, Endosense, Hansen Medical, Medtronic CryoCath LP, NIH, St. Jude Medical, Siemens, Thermedical. Honoraria; Significant; Abbott Laboratories/Topera, Aperture Diagnostics $0, Biosense Webster $0, Boston Scientific $0, CardioFocus $0, CardioInsight $0, Johnson & Johnson Healthcare Systems $0, Johnson & Johnson $0, MediaSphere Medical, , Medtronic CryoCath $0, Siemens $0, St. Jude Medical $0, Topera. Other; Significant; Royalties: St. Jude Medical, Royalties: Analyze-AVW technology, Royalties: Wiley and Sons.
- © 2016 by American Heart Association, Inc.